NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

CytoMed Therapeutics Limited (GDTC) Stock Analysis

CytoMed Therapeutics Limited (GDTC) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

GDTC

$0.86

−$0.02 (−2.16%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GDTC with… →

GDTC Key Statistics

As of Sep 4, 2026
Trading
Open
$0.93
Previous Close
$0.88
Day's Range
0.85–0.93
52-Week Range
0.68–3.68
Volume
16.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.05
Valuation
Market Cap
$10.19M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
11.84
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.27
Financials (FY)
Revenue (FY)
$324.39K+366.74%
Net Income (FY)
−$3.98M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
11.83M
1-Year Return
−54.68%
Dividend and dates
Avg Volume
80.88K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

GDTC Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−35.51%
2025−60.74%
2024−30.61%
2023 (partial year)+22.50%

As of September 4, 2026.

GDTC Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$324.39K−$3.98M−1227.1%
2024$69.50K−$2.52M−3621.1%
2023$0.00−$4.13M—
2022$0.00−$3.13M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$324.39K$256.40K−$4.24M−$3.98M−1227.1%
2024$69.50K$52.38K−$3.13M−$2.52M−3621.1%
2023$0.00$0.00−$3.84M−$4.13M—
2022$0.00$0.00−$1.86M−$3.13M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

GDTC Valuation vs Biotechnology Median

Median of 656 stocks
MetricGDTCBiotechnology medianvs median
P/S ratio11.8415.2622% below
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values CytoMed Therapeutics Limited (GDTC) at $10.19M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 42.

GDTC last closed at $0.86 on September 4, 2026. That is −$0.02 (−2.16%) against the previous close. The 52-week range on file runs from $0.68 to $3.68. The latest close sits 26.62% above that 52-week low.

Financial Health

In fiscal 2025, CytoMed Therapeutics Limited reported revenue of $324.39K. That is +366.74% against the prior fiscal year, when revenue was $69.50K. The same year closed with a net loss of $3.98M. Profit margin runs at 0%. Trailing earnings per share are −0.27.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $324.39K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 11.84. On price-to-sales that is 22.45% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is −54.68%. Across 3 years the annualized return works out at −37.22%. Beta against the wider market is reported at 0.05. Daily returns over the trailing 3 years annualize to a volatility of 87.17%.

Growth & Income

No dividend is on file for GDTC.

2026 is still running; the price is −35.51% year to date. The strongest complete calendar year on file is 2024 at −30.61%; the weakest is 2025 at −60.74%.

Peer Comparison

CytoMed Therapeutics Limited (GDTC) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
CytoMed Therapeutics Limited GDTC $10.19M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. CytoMed Therapeutics Limited has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About CytoMed Therapeutics Limited

CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.

Visit website →